Ivacaftor (trade name Kalydeco developed as VX-770) is a drug approved for patients with a certain mutation of cystic fibrosis which accounts for 4–5% cases of cystic fibrosis. Ivacaftor was developed by Vertex Pharmaceuticals in conjunction with the Cystic Fibrosis Foundation. It is one of the most expensive drugs costing over $300000 per year and doctors who developed the drug have criticized Vertex for charging so much.
This page contains content from the copyrighted Wikipedia article "Ivacaftor"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
